Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
Open Access
- 28 June 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 18 (1), 698
- https://doi.org/10.1186/s12885-018-4612-2
Abstract
The advent of tyrosine kinase inhibitors (TKIs) has changed the treatment of RAI refractory, unresectable recurrent differentiated thyroid cancer (DTC), which was formerly treated with multidisciplinary remedies. Here we describe the case of a 64-year-old woman who underwent total thyroidectomy with tracheal resection and suffered from a recurrent tumor in the neck and multiple lung and bone metastases 3 and 11 months, respectively, after the operation. Multimodal therapies, RI (I-131), EBRT, and taxane-based chemotherapy were ineffective, and sorafenib was started as a TKI. However, because of disease progression, sorafenib was replaced by lenvatinib after 9 months. The effect of lenvatinib has continued for more than 1 year and 9 months, and the patient has well survived. During the treatment period, a tracheal pin-hole fistula suddenly emerged, which was naturally cured by the temporary cessation of lenvatinib. Adverse events such as hypertension, proteinuria, and diabetes as innate complications have been successfully managed until the present according to our institute regulations. Even where multimodal treatment was ineffective, lenvatinib was suggested to be an alternative treatment option for RAI refractory recurrent DTC and patient could have a chance to be controlled successfully.Keywords
This publication has 20 references indexed in Scilit:
- Operative management of locally advanced, differentiated thyroid cancerSurgery, 2016
- Selective use of sorafenib in the treatment of thyroid cancerDrug Design, Development and Therapy, 2016
- Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesDrug Design, Development and Therapy, 2016
- Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local FailureThyroid®, 2015
- Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory PatientsThe Oncologist, 2015
- Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer ModelsJournal of Thyroid Research, 2014
- Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid CancerThyroid®, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibBiologics: Targets and Therapy, 2014
- Differentiated Thyroid Cancer with Extrathyroidal Extension: Prognosis and the Role of External Beam RadiotherapyJournal of Thyroid Research, 2010